HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen


Autoria(s): SAENZ, R.; SOUZA, C. da Silva; HUANG, C. -T.; LARSSON, M.; ESENER, S.; MESSMER, D.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2010

Resumo

There is a need for new adjuvants that will induce immune responses to subunit vaccines. We show that a short peptide, named Hp91, whose sequence corresponds to an area within the endogenous molecule high mobility group box (HMGB1) protein 1 potentiates cellular immune responses to peptide antigen and cellular and humoral immune responses to protein antigen in vivo. Hp91 promoted the in vivo production of the immunomodulatory cytokines, IFN-gamma, TNF-alpha, IL-6, and IL-12 (p70), as well as antigen-specific activation of CD8+ T cells. These results demonstrate the ability of a short immunostimulatory peptide to serve as an adjuvant for subunit vaccines. (C) 2010 Elsevier Ltd. All rights reserved.

National Institutes of Health (NCI/NIH)[5 U54 CA119335]

Swedish Research Council[AI52731]

Swedish International Development Cooperation Agency

SIDA

VINNMER (Vinnova)

Identificador

VACCINE, v.28, n.47, p.7556-7562, 2010

0264-410X

http://producao.usp.br/handle/BDPI/24114

10.1016/j.vaccine.2010.08.054

http://dx.doi.org/10.1016/j.vaccine.2010.08.054

Idioma(s)

eng

Publicador

ELSEVIER SCI LTD

Relação

Vaccine

Direitos

restrictedAccess

Copyright ELSEVIER SCI LTD

Palavras-Chave #HMGB-1 peptides #Adjuvants #Vaccine #Immunotherapy #Dendritic cells #TOLL-LIKE RECEPTORS #MOBILITY GROUP BOX-1 #PLASMACYTOID DENDRITIC CELLS #GLYCATION END-PRODUCTS #TUMOR-NECROSIS-FACTOR #VACCINE ADJUVANTS #FUTURE-PROSPECTS #NECROTIC CELLS #CPG DNA #HMGB1 #Immunology #Medicine, Research & Experimental
Tipo

article

original article

publishedVersion